Covalon CEO speaks at Medical Devices Symposium
October 27, 2008
MISSISSAUGA, ONTARIO--(Marketwire - October 27, 2008) – Dr. Frank DiCosmo, President and CEO of Covalon Technologies Ltd. (TSX VENTURE: COV) spoke at the Biomedical Devices Special Symposium organized by the Licensing Executives Society (USA and Canada) Inc., a professional society comprised of over 6,000 members engaged in the transfer, use, development, manufacture and marketing of intellectual property.
Dr. Frank DiCosmo was invited to speak on a panel that examined the perspectives of:
- biomedical device companies that have been acquired or have merged to achieve commercialization of their products;
- companies that have acquired other medical device makers as part of their strategy for growth;
- companies that have optimized growth by commercialization of their technologies and products; and
- venture capital companies who view acquisition as the optimal exit strategy.
Dr. DiCosmo commented, “More than ever, strategic partnerships will deliver unique value to the medical devices marketplace for all companies, whether small or large. Shifting trends are creating huge opportunities for commercialization within the biomedical device sector including changes in reimbursement policies, accountability for results, globalization of emerging markets and dramatic advances in R & D platforms. For companies like Covalon, with huge footprints of medical technologies, the opportunities are enormous.”
About Covalon
Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. Management assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
For further information please contact:
Frank DiCosmo, Ph.D.
President & CEO
Covalon Technologies Ltd.
T: (905) 568-8400 x 246
F: (905) 568-5200
www.covalon.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.
